medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2015; 14 (2)


Reasons for HCV non-treatment in underserved African Americans: Implications for treatment with new therapeutics

Schaeffer S, Khalili M

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 234-242
Archivo PDF: 106.95 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.

  2. Daniel S. Chronic hepatitis C treatment patterns in African American patients: An update. Am J Gastroenterol 2005; 100: 716-22.

  3. Crosse K, Umeadi OG, Anania FA, Laurin J, Papadimitriou J, Drachenberg C, Howell CD. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2004; 2: 463-8.

  4. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: Summary of a workshop. Gastroenterology 2000; 119: 1385-96.

  5. Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: Do they alter their decision with time? Dig Dis Sci 2007; 52: 1168-76.

  6. Borum ML, Igiehon E, Shafa S. African Americans may differ in their reasons for declining hepatitis C therapy compared to non-African Americans. Dig Dis Sci 2009; 54: 1604; author reply 1604-05.

  7. Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, et al. Racial differences in hepatitis C treatment eligibility. Hepatology 2011; 54: 70-8.

  8. Hare CB, Morris JA, Chu A, Gotz V, Loveland JJ, Hodes D, Klaskala W. Comparison of characteristics of treated and non-treated patients with hepatitis C infection. Pharmacoepidemiol Drug Saf 2006; 15: 71-6.

  9. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 369: 678-9.

  10. Cheung RC, Currie S, Shen H, Ho SB, Bini EJ, Anand BS, Bräu N, et al. Chronic hepatitis C in Latinos: Natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005; 100: 2186-93.

  11. Srivastava S, Bertagnolli M, Lewis JH. Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: Results in treatment- naïve patients in a university liver clinic. J Natl Med Assoc 2005; 97: 1703-07.

  12. Schackman BR, Teixeira PA, Beeder AB. Offers of hepatitis C care do not lead to treatment. J Urban Health 2007; 84: 455-58.

  13. Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for nontreatment of hepatitis C in veterans in care. J Viral Hepat 2005; 12: 81-5.

  14. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, et al. Heart disease and stroke statistics—2013 update: A report from the American Heart Association. Circulation 2013; 127: e6-e245.

  15. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.

  16. Guy J, Yee HF. Health disparities in liver disease: Time to take notice and take action. Hepatology 2009; 50: 309-13.

  17. Surjadi M, Torruellas C, Ayala C, Yee HF, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci 2011; 56: 213-9.

  18. Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int 2013; 33: 999-1007.

  19. Bindman AB, Chen A, Fraser JS, Yee HF, Ofman D. Healthcare reform with a safety net: Lessons from San Francisco. Am J Manag Care 2009; 15: 747-50.

  20. Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academies Press; 2010.

  21. Centers for Disease Control and Prevention. Establishing a Holistic Framework to Reduce Inequities in HIV, Viral Hepatitis, STDs, and Tuberculosis in the United States. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; October 2010. Available at: www.cdc.gov/socialdeterminants. Accessed November 11, 2013.

  22. U.S. Department of Health and Human Services. Combating the silent epidemic of viral hepatitis: Action plan for the prevention, care, and treatment of viral hepatitis (2014- 2016). Available at: http://aids.gov/pdf/viral-hepatitisaction- plan.pdf. Accessed July 1st, 2014.

  23. San Francisco General Hospital and Trauma Center annual report, fiscal year 2012-13. Available at: http://www.sfdph.org/dph/files/SFGHdocs/2012- 2013AnnualReport131031.pdf. Accessed on November 1st, 2013.

  24. Clark PJ, Muir AJ. Overcoming barriers to care for hepatitis C. N Engl J Med 2012; 366: 2436-8.




2020     |     www.medigraphic.com